Drug delivery and therapeutic impact of extended-release acetylsalicylic acid

Future Cardiology

Volumn 12, Issue 1, 2016, Pages 45-58

  Bliden, Kevin P ^a   Patrick, Jeff ^b   Pennell, Andrew T ^b   Tantry, Udaya S ^a   Gurbel, Paul A ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b New Haven Pharmaceuticals   (United States)

Author keywords

acetylsalicylic acid; antiplatelet; cardiovascular disease; diabetes; Durlaza; extended release; microcapsule; secondary prevention; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DELAYED RELEASE FORMULATION;

ANALGESIC ACTIVITY; ANTICOAGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED DRUG RELEASE; HEALTH PROGRAM; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; MEDICAL TECHNOLOGY; META ANALYSIS (TOPIC); PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; CARDIOVASCULAR DISEASES; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG RESISTANCE; PHARMACOLOGY; THERAPEUTIC USE;

ASPIRIN; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; SECONDARY PREVENTION;

EID: 84953279636     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.60     Document Type: Review

References (80)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131(4), e29-e322 (2015).
2. Centers for Disease Control and Prevention. Heart disease and stroke prevention address the nations leading killers (2011). www.cdc.gov/chronicdisease/resources/ publications/aag/pdf/2011/heart-disease-and-stroke-aag-2011.pdf.
3. Giorda CB, Avogaro A, Maggini M, et al. Recurrence of cardiovascular events in patients with Type 2 diabetes: epidemiology and risk factors. Diabetes Care 31(11), 2154-2159 (2008).
4. van der Heijden AA, Vant Riet E, Bot SD, et al. Risk of a recurrent cardiovascular event in individuals with Type 2 diabetes or intermediate hyperglycemia: the Hoorn Study. Diabetes Care 36(11), 3498-3502 (2013).
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229-234 (1998).
6. Cubbon RM, Abbas A, Wheatcroft SB, et al. Diabetes mellitus and mortality after acute coronary syndrome as a first or recurrent cardiovascular event. PLoS ONE 3(10), e3483(2008).
7. American Diabetes Association. Position statement Section 8: cardiovascular disease and risk management. Diabetes Care 38(Suppl.), S49-S57 (2015).
8. Smith SC Jr, Benjamin EJ, Bonow RO, et al. The World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124(22), 2458-2473 (2011).
9. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J. Am. Coll. Cardiol. 51(19), 1829-1843 (2008).
10. Grove EL. Antiplatelet effect of aspirin in patients with coronary artery disease. Dan. Med. J. 59(9), B4506 (2012).
11. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231(25), 232-235 (1971).
12. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J. Am. Coll. Cardiol. 46(9), 1705-1709 (2005).
13. Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr. Pharm. Des. 18(33), 5197-5214 (2012).
14. Gurbel PA, Mahla E, Antonino MJ, Tantry US. Response variability and the role of platelet function testing. J. Invasive Cardiol. 21(4), 172-178 (2009).
15. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog. Cardiovasc. Dis. 52(2), 141-152 (2009).
16. Patrignani P, Tacconelli S, Piazuelo E, et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J. Thromb. Haemost. 12(8), 1320-1330 (2014).
17. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353(22), 2373-2383 (2005).
18. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37(8), 2153-2158 (2006).
19. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311(19), 1206-1211 (1984).
20. Tang M, Mukundan M, Yang J, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol. Exp. Ther. 319(3), 1467-1476 (2006).
21. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72(6), 1177-1184 (1985).
22. Behnke O, Forer A. From megakaryocytes to platelets: platelet morphogenesis takes place in the bloodstream. Eur. J. Haematol. Suppl. 61, 3-23 (1998).
23. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), Se89-Se119S (2012).
24. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J. Clin. Invest. 61(2), 314-319 (1978).
25. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J. Thromb. Haemost. 9(1), 185-191 (2011).
26. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69(6), 1366-1372 (1982).
27. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb. Haemost. 101(1), 151-156 (2009).
28. Vaduganathan M, Alviar CL, Arikan ME, et al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am. Heart J. 156(5), 1002-1002 (2008).
29. Mijovic R, Kovacevic N, Zarkov M, Stosic Z, Cabarkapa V, Mitic G. Reticulated platelets and antiplatelet therapy response in diabetic patients. J. Thromb. Thrombolysis 40(2), 203-210 (2015).
30. Arazi HC, Doiny DG, Torcivia RS, et al. Impaired anti-platelet effect of aspirin, inflammation and platelet turnover in cardiac surgery. Interact. Cardiovasc. Thorac. Surg. 10(6), 863-867 (2010).
31. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678), 1849-1860 (2009).
32. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
33. Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J. Gen. Intern. Med. 26(11), 1336-1344 (2011).
34. Berger JS, Sallum RH, Katona B, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am. Heart J. 164(2), 153-162 (2012).
35. Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), S776-S814 (2008).
36. Gurbel P, Tantry US. Monitoring of antiplatelet therapy. In:Platelets. Michelson AD (Eds), Elsevier, Waltham, MA, USA, 602-612 (2013).
37. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25), 3156-3164 (2007).
38. Tantry US, Gesheff M, Liu F, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: what progress has been made? Expert. Opin. Pharmacother. 15(17), 2553-2564 (2014).
39. Hanley AJ, Karter AJ, Williams K, et al. Prediction of Type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 112(24), 3713-3721 (2005).
40. Tasdemir E, Toptas T, Demir C, Esen R, Atmaca M. Aspirin resistance in patients with Type II diabetes mellitus. Ups. J. Med. Sci. 119(1), 25-31 (2014).
41. Cetin M, Kiziltunc E, Cetin ZG, et al. Acetylsalicylic acid resistance in patients with Type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease. Pak. J. Med. Sci. 30(3), 539-544 (2014).
42. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. Heart J. 153(2), 175-181 (2007).
43. Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis 2012, 376721 (2012).
44. Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy. Circulation 63(3), 546-551 (1981).
45. Winocour PD, Laimins M, Colwell JA. Platelet survival in streptozotocin-induced diabetic rats. Thromb. Haemost. 51(3), 307-312 (1984).
46. Larsen SB, Grove EL, Hvas AM, Kristensen SD. Platelet turnover in stable coronary artery disease -influence of thrombopoietin and low-grade inflammation. PLoS ONE 9(1), e85566 (2014).
47. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88(3), 230-235 (2001).
48. Salama MM, Morad AR, Saleh MA, Sabri NA, Zaki MM, ElSafady LA. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors. J. Clin. Pharm. Ther. 37(6), 630-636 (2012).
49. Bednar F, Osmancik P, Hlavicka J, Jedlickova V, Paluch Z, Vanek T. Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery. J. Thromb. Thrombolysis 27(4), 394-399 (2009).
50. Kammerer I, Bach J, Saggau W, Isgro F. Functional evaluation of platelet aspirin resistance after on-pump coronary bypass grafting using multiple aggregation tests. Thorac. Cardiovasc. Surg. 59(7), 425-429 (2011).
51. Labuz-Roszak B, Pierzchala K, Tyrpien K. Resistance to acetylsalicylic acid in patients with Type 2 diabetes mellitus is associated with lipid disorders and history of current smoking. J. Endocrinol. Invest. 37(4), 331-338 (2014).
52. Smith JP, Haddad EV, Taylor MB, et al. Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension 59(3), 719-725 (2012).
53. Fateh-Moghadam S, Plockinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with Type 2 diabetes. Acta Diabetol. 42(2), 99-103 (2005).
54. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108(5), 542-547 (2003).
55. Zaccardi F, Rocca B, Pitocco D, Tanese L, Rizzi A, Ghirlanda G. Platelet mean volume, distribution width, and count in Type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. Diabetes Metab. Res. Rev. 31(4), 402-410 (2015).
56. Lee EY, Kim SJ, Song YJ, Choi SJ, Song J. Immature platelet fraction in diabetes mellitus and metabolic syndrome. Thromb. Res. 132(6), 692-695 (2013).
57. Ibrahim H, Schutt RC, Hannawi B, DeLao T, Barker CM, Kleiman NS. Association of immature platelets with adverse cardiovascular outcomes. J. Am. Coll. Cardiol. 64(20), 2122-2129 (2014).
58. Cesari F, Marcucci R, Gori AM, et al. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb. Haemost. 109(5), 846-853 (2013).
59. Slavka G, Perkmann T, Haslacher H, et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 31(5), 1215-1218 (2011).
60. Henry P, Vermillet A, Boval B, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb. Haemost. 105(2), 336-344 (2011).
61. Wrtz M, Hvas AM, Jensen LO, et al. 24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis. Int. J. Cardiol. 175(2), 274-279 (2014).
62. DiChiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56(12), 3014-3019 (2007).
63. Capodanno D, Patel A, Dharmashankar K, et al. Pharmacodynamic effects of different aspirin dosing regimens in Type 2 diabetes mellitus patients with coronary artery disease. Circ. Cardiovasc. Interv. 4(2), 180-187 (2011).
64. Dusse LM, Freitas LG. Clinical applicability of reticulated platelets. Clin. Chim. Acta 439, 143-147 (2015).
65. Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br. J. Haematol. 17(3), 225-229 (1969).
66. Kieffer N, Guichard J, Farcet JP, Vainchenker W, Breton-Gorius J. Biosynthesis of major platelet proteins in human blood platelets. Eur. J. Biochem. 164(1), 189-195 (1987).
67. Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J. Thromb. Haemost. 5(3), 490-496 (2007).
68. Mangalpally KKR, Siqueiros-Garcia A, Vaduganathan M, Dong JF, Kleiman NS, Guthikonda S. Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. J. Thromb. Thrombolysis 30(3), 251-262 (2010).
69. Wrtz M, Grove EL, Wulff LN, et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC. Cardiovasc. Interv. 3(8), 828-835 (2010).
70. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P. Dose-and time-dependent antiplatelet effects of aspirin. Thromb. Haemost. 95(4), 652-658 (2006).
71. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 82(3), 897-902 (1990).
72. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79(4), 733-743 (1989).
73. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am. J. Med. 125(9), 882-887 (2012).
74. Laliberté F, Bookhart BK, Nelson WW, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 6(3), 213-224 (2013).
75. Patrick J, Dillaha L, Armas D, Sessa W. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. Postgrad. Med. 127(6), 573-580 (2015).
76. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am. J. Med. 119(8), 624-638 (2006).
77. Brown N, May JA, Wilcox RG, et al. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br. J. Clin. Pharmacol. 48(1), 57-62 (1999).
78. Donnelly MT, Stack WA, Richardson P, et al. Microencapsulated aspirin, Asacard, reduces endoscopic damage in healthy volunteers compared with conventional encapsulated aspirin [abstract G0440]. Gastroenterology 114, A107(1998).
79. De Feo P, Boris JM, Maffeis C. Lifestyle modification strategies to counteract the world epidemic growth of obesity and diabetes. Biomed. Res. Int. 2014, 640409 (2014).
80. Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob. Cardiol. Sci. Pract. 2014(3), 291-308 (2014).